+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Biopharmaceutical Excipients Market - Global Outlook and Forecast 2022-2027

  • PDF Icon

    Report

  • 317 Pages
  • July 2022
  • Region: Global
  • Arizton
  • ID: 5639213
UP TO OFF until Dec 31st 2022
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global biopharmaceutical excipients market is expected to grow at a CAGR of 7.56% during 2022-2027.

Excipients are fundamental components of any biopharmaceutical drug product, which act as active ingredients, stability enhancers, emulsifying and suspending agents, binders, preservatives, antioxidants, and lubricants. These differ from prodrugs in manufacturing or are present in a finished pharmaceutical product dosage form. Excipients have targeted roles, ranging from protecting the API to easing the manufacturing process, which, in turn, drives the need and stipulation of excipients for developing effective formulations.

The constant shift of trends in the pharma sector, including new drug development, continuous manufacturing, and innovative drug technologies, has donated to a surge in demand for excipients with advanced functions. Between 40-70% of marketed drugs and up to 90% of all new chemical entities (NCEs) registered to suffer from poor water solubility. This can have significant negative consequences on the bioavailability of the active pharmaceutical ingredient (API), potentially impacting the therapeutic effect. The market for solubility-enhancing excipients and related technologies is proliferating to tackle the problem.

High-concentration biologic formulations account for an increasing percentage of the drug development pipeline as drug manufacturers seek to offer advanced therapeutics that the patient or caregiver can administer in the home setting. These high concentrations include protein-protein interactions due to higher viscosities. Excipients can help minimize these interactions without negatively impacting protein stability and other aspects of biologic formulations. This is driving a shift towards carefully selected combinations of viscosity-reducing excipients.

Biologics- Pipeline and Product Approvals, a Major driver for Biopharmaceutical Excipients Market


With a growing number of infectious diseases and cancers, there is a high demand for various biologic drugs. Innovative biopharmaceutical companies are continuously operating with stakeholders across the R&D landscape for the expansion of newer ways to treat such diseases. To date, 258 vaccines are in the pipeline for treating and preventing severe infectious diseases. According to a study, trends in global vaccine R&D found that the proportion of new vaccine candidates entering all stages of clinical development increased by 3-5 percentage points over the past two decades. Small and medium-sized companies accounted for nearly twice as many new Phase I vaccine trials as large companies, but large companies dominated late-stage (Phase III) vaccine trials.

The biologics industry is increasing, with an estimated 40% of biopharmaceuticals in the industry pipeline. Biological products are the fastest-growing class of therapeutic products, especially in the U.S. Since 2000, more than 475 new prescription medicines (new molecular entities (NMEs) and new biologics license applications) have been approved for use by the U.S. Food and Drug Administration. The growing approvals of biopharmaceuticals will likely increase the need for novel excipients used in their formulation and contribute to market growth.

Novel Excipients Creating a Major Shift from Traditional Excipients


As drug substances become increasingly complex, formulation challenges will continue to grow. Novel excipients can significantly impact drug development and, by extension, the number and types of treatments available to patients. A novel excipient differs from an excipient in that it has not been previously used in an approved drug. In an essential step for modernizing drug formulation and biopharmaceutical development, FDA is launching a program to test the safety and suitability of novel inactive ingredients for use in new drugs and biologics. The aim is to encourage sponsors of clinical trials to formulate innovative therapies with those new excipients that FDA finds acceptable for use under this program.

Growing Trend Outsourcing the Manufacture of Biopharmaceutical Excipients


In today's market, pharmaceutical companies cite improved quality and faster time to market as the main reasons for outsourcing business functions to contract research organizations (CROs) and contract development and research organizations (CDMOs). Formulators are increasingly facing complexity with ingredients in their drug products and incorporating multiple active elements, increasing regulations, changing social and consumer preferences, and environmental implications impact production and eventual decomposition. This led to the outsourcing of ingredients manufacturing which also includes excipients as a significant component.

Challenges Restraining the Growth of Biopharmaceutical Excipients


The quality and safety of pharmaceutical products are the top concerns of regulators. In recent years, regulatory agencies have strengthened their position on preventing drug adulteration in active pharmaceutical ingredients (API) and excipients by enacting new regulations. However, the current regulatory landscape or lack of an independent excipient approval pathway can limit the entrance of new excipients into the market and, subsequently, new drug products.

Many challenges are associated with excipient quality management, managing extended supply chains, and developing certification schemes for producing and supplying excipients. Not satisfactorily meeting these challenges creates the potential for counterfeit or substandard excipients to enter the supply chain. Furthermore, several challenges also exist in formulating biological drug products using excipients due to the complexity and fragility of the active compounds.

Impact of COVID-19 on Biopharmaceutical Excipients


During the pandemic, companies rushed to develop new biopharmaceuticals, drug products, vaccines, and re-purpose older drug products. Due to this, the importance of the critical function excipients in these products has risen. Excipients played a vital role in the progression of new biopharmaceuticals, pharmaceuticals, and vaccines to fight COVID-19 and other diseases. Therefore, various excipients are required to stabilize biologics and vaccines during processing and storage. Selection and use of the appropriate excipients enabled the development of novel therapies and robust pharmaceutical products.

By Excipient


The global biopharmaceutical excipients market is segmented by bulking agents, solubilizers & surfactants, buffering & tonicity agents, and others. In 2021, bulking agents accounted for the highest share of 39% and were expected to have the most significant incremental growth during the forecast period.

By Biologics


Biologics included monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapy, interferons, growth factors, and others. In 2021, monoclonal antibodies accounted for the highest share of 45.04% and were expected to have the most significant incremental growth during the forecast period. A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to an individual parent cell. Monoclonal antibodies can have monovalent affinity, binding only to the same epitope (the part of an antigen recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different antibody-secreting plasma cell lineages. Bispecific monoclonal antibodies can also be engineered by increasing the therapeutic targets of one monoclonal antibody to two epitopes.

Vaccines are inherently less stable than small molecules, and formulation development is often challenging with stringent product development timelines. Their complex molecular structure, lack of well-defined stability-indicating assays, and a multitude of degradation mechanisms create significant hurdles for the formulation development of vaccines.

By Scale of Operation


The global biopharmaceutical excipients market is segmented by commercial and research. In 2021, retail accounted for the highest share of 73.20% and was expected to grow with the highest incremental and absolute growth of $862.44 million and 56.60%, respectively, during the forecast period.

With growing infectious diseases and the onset of epidemics and pandemics, there is a massive demand for manufacturing a billion doses of biologics within months. With a greater uptake of biologics, the need for manufacturing high quantities of these drugs is increasing. Biopharmaceutical manufacturing large-scale drug substances and products is a highly challenging task. With a high patient population in the commercial phase, the rapid development of large-scale production is a critical step that requires enormous volumes of ingredients.

By End-user


The global biopharmaceutical excipients market is segmented by pharma & biotech companies, CMOs & CDMOs, and academic & research institutes. In 2021, pharma & biotech companies accounted for the highest share of 57.63% and were expected to have the most significant incremental growth of $640.83 million during the forecast period.
With growing infectious diseases and the onset of epidemics and pandemics, there is a massive demand for manufacturing a billion doses of biologics within months. With a greater uptake of biologics, the need for manufacturing high quantities of these drugs is increasing. Biopharmaceutical manufacturing large-scale drug substances and products is a highly challenging task. With a high patient population in the commercial phase, the rapid development of large-scale production is a critical step that requires enormous volumes of ingredients.

By Geography


In 2021, North America dominated the global biopharmaceutical excipients market with 34.10%. However, APAC is likely the fastest-growing region in the worldwide biopharmaceutical excipients market, with the highest CAGR of 9.01% during the forecast period. The North American biopharmaceuticals market is well established, with prominent biopharmaceutical manufacturing companies based in the region. The rise in drug development has significantly increased the demand for biopharmaceutical excipients in this region. The US is the major revenue contributor in North America mainly due to an increase in the vaccine market, reflecting the growth in awareness of vaccinations and their benefits against infectious diseases.

Increasing populations, the emergence of infections, demand for vaccines, improved biopharma facilities, and the advent of COVID-19 are significant factors boosting the demand for biopharmaceutical excipients in Europe. However, APAC is the fastest-growing region for biopharmaceutical excipients. Emerging countries such as China and Japan are the major players due to low labor costs and increased outsourcing of inorganic and organic chemicals manufacturing. Latin America, the Middle East, & Africa accounted for minor shares in the global biopharmaceutical excipients market.

COMPETITIVE LANDSCAPE


The global biopharmaceutical excipients market is fragmented, with vendors ranging from emerging mid-sized to established players contributing to its revenue. Most of the leading players focus on implementing various strategies such as product launches and approvals, marketing, and promotional activities, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market. For instance, in 2020, DFE Pharma launched a new portfolio of biopharmaceutical excipients for stabilizing biologics to capitalize on increasing growth in the biologics sector. In the same year, MilliporeSigma agreed with ReForm Biologics to commercialize ReForm's excipients used in biotherapeutic formulations.

Established players that accounted for a significant share in the global biopharmaceutical excipients market include Merck KGaA, DFE Pharma, Avantor, BASF SE, Evonik Industries AG, and Rouquette Freres. Other prominent vendors that are emerging in the global biopharmaceutical excipients market are Aceto, Ashland Global Holdings, Biohale, Biospectra, Clariant, Colorcon, Dow Chemical Industries, Fuji Chemical Industries, IMCD, Innophos, JRS Pharma, Kirsch Pharma, Novo Nordisk, Pfanstiehl, Pharmonix Biologicals, Sigachi Industries.

Vendors

  • Merck KGAA
  • BASF SE
  • Avantor
  • Evonik Industries
  • Roquette Freres

Other Prominent Vendors

  • Aceto
  • Angus Chemical
  • Apothecon
  • Ashland Global
  • BioSpectra
  • BOC Sciences
  • C.G. Group
  • Clariant
  • Colorcon
  • DFE Pharma
  • DOW
  • Eastman Chemical
  • IMCD N.V.
  • Innophos
  • Invitria
  • JRS Pharma
  • Kirsch Pharma
  • Meggle
  • Novo Nordisk
  • PFANSTIEHL
  • Pharmonix
  • Shin-Etsu Chemical
  • Sigachi Industries
  • Spectrum Chemical
  • Tereos
  • The Lubrizol
  • Wacker Chemie

KEY QUESTIONS ANSWERED


1. HOW BIG IS THE BIOPHARMACEUTICAL EXCIPIENTS MARKET?
2. WHAT IS THE BIOPHARMACEUTICAL EXCIPIENTS MARKET GROWTH?
3. WHO ARE THE MARKET LEADERS IN THE GLOBAL BIOPHARMACEUTICAL INDUSTRY?
4. WHAT ARE THE TOP TRENDS DRIVING THE MARKET GROWTH?

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of the Study
4.3.1 Market Segmentation by Excipient
4.3.2 Market Segmentation by Biologics
4.3.3 Market Segmentation by Scale of Operation
4.3.4 Market Segmentation by End-User
4.3.5 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.2 Market Synopsis
7.2.1 Global Biopharmaceutical Excipients Market Scenario
7.2.2 Biologics - Pipeline and Product Approvals, a Major Driver for Biopharmaceutical Excipients
7.2.3 Novel Excipients Creating a Major Shift from Traditional Excipients
7.2.4 Growing Trend of Outsourcing the Manufacture of Biopharmaceutical Excipients
7.2.5 Challenges Restraining the Growth of Biopharmaceutical Excipients
7.2.6 Impact of Covid-19 on Biopharmaceutical Excipients
7.2.7 Global Biopharmaceutical Excipients: Market Segmentations
7.2.8 Competitive Landscape
8 Market Opportunities & Trends
8.1 Emerging Demand for Novel Excipients in Drug Product Development
8.2 High Demand for Vaccines and Cell & Gene Therapy-Based Excipients
8.3 Exhaustive Pipeline of Biologics & Biosimilars
8.4 Growing Penetration of Biopharmaceutical Drugs
9 Market Growth Enablers
9.1 Growing Prevalence of Cancer and Infectious Diseases
9.2 Rising Number of Product Approvals for Biologics
9.3 Increasing Need for Outsourcing Biopharmaceutical Excipient Manufacturing
9.4 Emerging Need for Multi-Functional Excipients
10 Market Restraints
10.1 Regulatory Challenges in Manufacturing Biopharmaceutical Excipients
10.2 Supply Chain and Integrity Issues With Biopharmaceutical Excipients
10.3 Challenges of Formulating Biopharmaceutical Excipients
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.2.1 Insights by Excipient
11.2.2 Insights by Biologics
11.2.3 Insights by Scale of Operation
11.2.4 Insights by End-Users
11.2.5 Insights by Geography
11.2.6 Impact of Covid-19
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 Excipient
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Bulking Agents
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Bulking Agents: Geography Segmentation
12.4 Solubilizers & Surfactants
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Solubilizers & Surfactants: Geography Segmentation
12.5 Buffering & Tonicity Agents
12.5.1 Market Overview
12.5.2 Market Size & Forecast
12.5.3 Buffering & Tonicity Agents: Geography Segmentation
12.6 Others
12.6.1 Market Overview
12.6.2 Market Size & Forecast
12.6.3 Others: Geography Segmentation
13 Biologics
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Monoclonal Antibodies
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Monoclonal Antibodies: Geography Segmentation
13.4 Vaccines
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 Vaccines: Geography Segmentation
13.5 Others
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.5.3 Others: Geography Segmentation
14 Scale of Operation
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Commercial
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Commercial: Geography Segmentation
14.4 Research
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Research: Geography Segmentation
15 End-User
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Pharma & Biotech Companies
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.3.3 Pharma & Biotech Companies: Geography Segmentation
15.4 Cmos & Cdmos
15.4.1 Market Overview
15.4.2 Market Size & Forecast
15.4.3 Cmos & Cdmos: Geography Segmentation
15.5 Academic & Research Institutes
15.5.1 Market Overview
15.5.2 Market Size & Forecast
15.5.3 Academic & Research Institutes: Geography Segmentation
16 Geography
16.1 Market Snapshot & Growth Engine
16.2 Geographic Overview
17 North America
17.1 Market Overview
17.2 Market Size & Forecast
17.2.1 North America: Excipient
17.2.2 North America: Biologics
17.2.3 North America: Scale of Operation
17.2.4 North America: End-User
17.3 Key Countries
17.3.1 Us: Market Size & Forecast
17.3.2 Canada: Market Size & Forecast
18 Europe
18.1 Market Overview
18.2 Market Size & Forecast
18.2.1 Europe: Excipient
18.2.2 Europe: Biologics
18.2.3 Europe: Scale of Operation
18.2.4 Europe: End-User
18.3 Key Countries
18.3.1 Germany: Market Size & Forecast
18.3.2 France: Market Size & Forecast
18.3.3 Uk: Market Size & Forecast
18.3.4 Switzerland: Market Size & Forecast
18.3.5 Italy: Market Size & Forecast
18.3.6 Spain: Market Size & Forecast
19 Apac
19.1 Market Overview
19.2 Market Size & Forecast
19.2.1 Apac: Excipient
19.2.2 Apac: Biologics
19.2.3 Apac: Scale of Operation
19.2.4 Apac: End-User
19.3 Key Countries
19.3.1 China: Market Size & Forecast
19.3.2 Japan: Market Size & Forecast
19.3.3 South Korea: Market Size & Forecast
19.3.4 India: Market Size & Forecast
19.3.5 Australia: Market Size & Forecast
20 Latin America
20.1 Market Overview
20.2 Market Size & Forecast
20.2.1 Latin America: Excipient
20.2.2 Latin America: Biologics
20.2.3 Latin America: Scale of Operation
20.2.4 Latin America: End-User
20.3 Key Countries
20.3.1 Brazil: Market Size & Forecast
20.3.2 Mexico: Market Size & Forecast
20.3.3 Argentina: Market Size & Forecast
21 Middle East & Africa
21.1 Market Overview
21.2 Market Size & Forecast
21.2.1 Middle East & Africa: Excipient
21.2.2 Middle East & Africa: Biologics
21.2.3 Middle East & Africa: Scale of Operation
21.2.4 Middle East & Africa: End-User
21.3 Key Countries
21.3.1 Turkey: Market Size & Forecast
21.3.2 Saudi Arabia: Market Size & Forecast
21.3.3 Uae: Market Size & Forecast
21.3.4 South Africa: Market Size & Forecast
22 Competitive Landscape
22.1 Competition Overview
22.2 Market Share Analysis
22.2.1 Merck Kgaa
22.2.2 Basf Se
22.2.3 Avantor
22.2.4 Evonik Industries
22.2.5 Roquette Frères
22.2.6 Associated British Foods
23 Key Company Profiles
23.1 Merck Kgaa
23.1.1 Business Overview
23.1.2 Product Offerings
23.1.3 Key Strategies
23.1.4 Key Strengths
23.1.5 Key Opportunities
23.2 Basf Se
23.2.1 Business Overview
23.2.2 Product Offerings
23.2.3 Key Strategies
23.2.4 Key Strengths
23.2.5 Key Opportunities
23.3 Avantor
23.3.1 Business Overview
23.3.2 Product Offerings
23.3.3 Key Strategies
23.3.4 Key Strengths
23.3.5 Key Opportunities
23.4 Evonik Industries
23.4.1 Business Overview
23.4.2 Product Offerings
23.4.3 Key Strategies
23.4.4 Key Strengths
23.4.5 Key Opportunities
23.5 Roquette Frères
23.5.1 Business Overview
23.5.2 Product Offerings
23.5.3 Key Strategies
23.5.4 Key Strengths
23.5.5 Key Opportunities
23.6 Associated British Foods
23.6.1 Business Overview
23.6.2 Product Offerings
23.6.3 Key Strategies
23.6.4 Key Strengths
23.6.5 Key Opportunities
24 Other Prominent Vendors
24.1 Aceto
24.1.1 Business Overview
24.1.2 Product Offerings
24.2 Angus Chemical Company
24.2.1 Business Overview
24.2.2 Product Offerings
24.3 Apothecon Pharmaceuticals
24.3.1 Business Overview
24.3.2 Product Offerings
24.4 Ashland
24.4.1 Business Overview
24.4.2 Product Offerings
24.5 Biospectra
24.5.1 Business Overview
24.5.2 Product Offerings
24.6 Boc Sciences
24.6.1 Business Overview
24.6.2 Product Offerings
24.7 Cg Group
24.7.1 Business Overview
24.7.2 Product Offerings
24.8 Clariant
24.8.1 Business Overview
24.8.2 Product Offerings
24.9 Colorcon
24.9.1 Business Overview
24.9.2 Product Offerings
24.10 Dfe Pharma
24.10.1 Business Overview
24.10.2 Product Offerings
24.11 Dow
24.11.1 Business Overview
24.11.2 Product Offerings
24.12 Eastman Chemical Company
24.12.1 Business Overview
24.12.2 Product Offerings
24.13 Imcd
24.13.1 Business Overview
24.13.2 Product Offerings
24.14 Innophos
24.14.1 Business Overview
24.14.2 Product Offerings
24.15 Invitria
24.15.1 Business Overview
24.15.2 Product Offerings
24.16 Jrs Pharma
24.16.1 Business Overview
24.16.2 Product Offerings
24.17 Kirsch Pharma
24.17.1 Business Overview
24.17.2 Product Offerings
24.18 Meggle
24.18.1 Business Overview
24.18.2 Product Offerings
24.19 Novo Nordisk
24.19.1 Business Overview
24.19.2 Product Offerings
24.20 Pfanstiehl
24.20.1 Business Overview
24.20.2 Product Offerings
24.21 Pharmonix Biologicals
24.21.1 Business Overview
24.21.2 Product Offerings
24.22 Shin-Etsu Chemical
24.22.1 Business Overview
24.22.2 Product Offerings
24.23 Sigachi Industries
24.23.1 Business Overview
24.23.2 Product Offerings
24.24 Spectrum Chemical
24.24.1 Business Overview
24.24.2 Product Offerings
24.25 Tereos
24.25.1 Business Overview
24.25.2 Product Offerings
24.26 the Lubrizol Corporation
24.26.1 Business Overview
24.26.2 Product Offerings
24.27 Wacker Chemie
24.27.1 Business Overview
24.27.2 Product Offerings
25 Report Summary
25.1 Key Takeaways
25.2 Strategic Recommendations
26 Quantitative Summary
26.1 Excipient
26.1.1 North America: Excipient Segmentation
26.1.2 Europe: Excipient Segmentation
26.1.3 Apac: Excipient Segmentation
26.1.4 Latin America: Excipient Segmentation
26.1.5 Middle East & Africa: Excipient Segmentation
26.2 Biologics
26.2.1 North America: Biologics Segmentation
26.2.2 Europe: Biologics Segmentation
26.2.3 Apac: Biologics Segmentation
26.2.4 Latin America: Biologics Segmentation
26.2.5 Middle East & Africa: Biologics Segmentation
26.3 Scale of Operation
26.3.1 North America: Scale of Operation Segmentation
26.3.2 Europe: Scale of Operation Segmentation
26.3.3 Apac: Scale of Operation Segmentation
26.3.4 Latin America: Scale of Operation Segmentation
26.3.5 Middle East & Africa: Scale of Operation Segmentation
26.4 End-User
26.4.1 North America: End-User Segmentation
26.4.2 Europe: End-User Segmentation
26.4.3 Apac: End-User Segmentation
26.4.4 Latin America: End-User Segmentation
26.4.5 Middle East & Africa: End-User Segmentation
26.5 Geography
26.5.1 Bulking Agents: Geography Segmentation
26.5.2 Solubilizers & Surfactants: Geography Segmentation
26.5.3 Buffering & Tonicity Agents: Geography Segmentation
26.5.4 Other Excipients: Geography Segmentation
26.5.5 Monoclonal Antibodies: Geography Segmentation
26.5.6 Vaccines: Geography Segmentation
26.5.7 Other Biologics: Geography Segmentation
26.5.8 Commercial: Geography Segmentation
26.5.9 Research: Geography Segmentation
26.5.10 Pharma & Biotech Companies: Geography Segmentation
26.5.11 Cmos & Cdmos: Geography Segmentation
26.5.12 Academic & Research Institutes: Geography Segmentation
27 Appendix
27.1 Abbreviations

Companies Mentioned

  • Merck KGAA
  • BASF SE
  • Avantor
  • Evonik Industries
  • Roquette Freres
  • Aceto
  • Angus Chemical
  • Apothecon
  • Ashland Global
  • BioSpectra
  • BOC Sciences
  • C.G. Group
  • Clariant
  • Colorcon
  • DFE Pharma
  • DOW
  • Eastman Chemical
  • IMCD N.V.
  • Innophos
  • Invitria
  • JRS Pharma
  • Kirsch Pharma
  • Meggle
  • Novo Nordisk
  • PFANSTIEHL
  • Pharmonix
  • Shin-Etsu Chemical
  • Sigachi Industries
  • Spectrum Chemical
  • Tereos
  • The Lubrizol
  • Wacker Chemie

Methodology


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...